Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer

Autophagy

Volumn 13, Issue 3, 2017, Pages 608-624

  Eritja, Núria ^a   Chen, Bo Juen ^b   Rodríguez Barrueco, Ruth ^c   Santacana, Maria ^a   Gatius, Sònia ^a   Vidal, August ^d   Martí, Maria Dolores ^d   Ponce, Jordi ^d   Bergadà, Laura ^a   Yeramian, Andree ^a   Encinas, Mario ^a   Ribera, Joan ^a   Reventós, Jaume ^d   Boyd, Jeff ^e   Villanueva, Alberto ^f   Matias Guiu, Xavier ^a,d   Dolcet, Xavier ^a   Llobet Navàs, David ^c  

^a UNIVERSITY OF LLEIDA   (Spain)

^b NEW YORK GENOME CENTER   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^f CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

autophagy; endometrial cancer; kinase; lysosomes; MAPK JNK; PDX; sorafenib; targeted therapy

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ARTICLE; AUTOPHAGY; CANCER CELL LINE; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; CELL SURVIVAL; DRUG CYTOTOXICITY; ENDOMETRIUM CANCER; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; LETHALITY; LUNG METASTASIS; LYSOSOME; MACROAUTOPHAGY; NONHUMAN; RNA SEQUENCE; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE EXACERBATION; DRUG EFFECTS; DRUG SCREENING; ENDOMETRIUM TUMOR; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CELL LINE, TUMOR; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; FEMALE; HUMANS; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85010685628     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.1080/15548627.2016.1271512     Document Type: Article

References (95)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917; PMID:21351269; http://dx.doi.org/10.1002/ijc.25516
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65:5-29; PMID:25559415; http://dx.doi.org/10.3322/caac.21254
3. Sorosky JI. Endometrial cancer. Obstet Gynecol 2012; 120:383-97; PMID:22825101; http://dx.doi.org/10.1097/AOG.0b013e3182605bf1
4. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15:10-7; PMID:6822361; http://dx.doi.org/10.1016/0090-8258(83)90111-7
5. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497:67-73.
6. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2):an open-label, non-inferiority, randomised trial. Lancet 2010; 375:816-23; PMID:20206777; http://dx.doi.org/10.1016/S0140-6736(09)62163-2
7. Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H, Eisenhauer E, Bacon M, Tu D, Parmar MK. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials):pooled trial results, systematic review, and meta-analysis. Lancet 2009; 373:137-46; PMID:19070891; http://dx.doi.org/10.1016/S0140-6736(08)61767-5
8. Tangjitgamol S, See HT, Kavanagh J. Adjuvant chemotherapy for endometrial cancer. Int J Gynecol Cancer 2011; 21:885-95; PMID:21697679; http://dx.doi.org/10.1097/IGC.0b013e3182169239
9. Fleming GF. Systemic chemotherapy for uterine carcinoma:metastatic and adjuvant. J Clin Oncol 2007; 25:2983-90; PMID:17617530; http://dx.doi.org/10.1200/JCO.2007.10.8431
10. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases:targets for cancer therapy. Nat Rev Cancer 2004; 4:361-70; PMID:15122207; http://dx.doi.org/10.1038/nrc1360
11. Hunter T. The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine:its role in cell growth and disease. Philos Trans R Soc Lond B Biol Sci 1998; 353:583-605; PMID:9602534; http://dx.doi.org/10.1098/rstb.1998.0228
12. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010; 10:130-7; PMID:20094047; http://dx.doi.org/10.1038/nrc2787
13. Bruix J, Sherman M. Management of hepatocellular carcinoma:an update. Hepatology 2011; 53:1020-2; PMID:21374666; http://dx.doi.org/10.1002/hep.24199
14. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-34; PMID:17215530; http://dx.doi.org/10.1056/NEJMoa060655
15. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-109; PMID:15466206; http://dx.doi.org/10.1158/0008-5472.CAN-04-1443
16. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib:a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5:835-44; PMID:17016424; http://dx.doi.org/10.1038/nrd2130
17. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen CN, Jr, Spannuth WA, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007; 13:7487-95; PMID:18094433; http://dx.doi.org/10.1158/1078-0432.CCR-07-1017
18. McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD, Gynecologic Oncology Group. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers:a Gynecologic Oncology Group study. Gynecol Oncol 2007; 105:508-16; PMID:17306350; http://dx.doi.org/10.1016/j.ygyno.2007.01.019
19. Ninomiya Y, Kato K, Takahashi A, Ueoka Y, Kamikihara T, Arima T, Matsuda T, Kato H, Nishida J, Wake N. K-Ras and H-Ras activation promote distinct consequences on endometrial cell survival. Cancer Res 2004; 64:2759-65; PMID:15087391; http://dx.doi.org/10.1158/0008-5472.CAN-3487-2
20. Nimeiri HS, Oza AM, Morgan RJ, Huo D, Elit L, Knost JA, Wade JL, 3rd, Agamah E, Vokes EE, Fleming GF. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma:a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2010; 117:37-40; PMID:20117828; http://dx.doi.org/10.1016/j.ygyno.2010.01.013
21. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007; 104:19936-41; PMID:18077425; http://dx.doi.org/10.1073/pnas.0707498104
22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis:a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102:15545-50; PMID:16199517; http://dx.doi.org/10.1073/pnas.0506580102
23. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005; 280:35217-27; PMID:16109713; http://dx.doi.org/10.1074/jbc.M506551200
24. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66:11851-8; PMID:17178882; http://dx.doi.org/10.1158/0008-5472.CAN-06-1377
25. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Thng CH, Chow P, Ong HS, Chung A, Soo KC. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 2009; 13:2673-83; PMID:19220580; http://dx.doi.org/10.1111/j.1582-4934.2009.00692.x
26. Liu LP, Ho RL, Chen GG, Lai PB. Sorafenib inhibits hypoxia-inducible factor-1alpha synthesis:implications for antiangiogenic activity in hepatocellular carcinoma. Clin Cancer Res 2012; 18:5662-71; PMID:22929805; http://dx.doi.org/10.1158/1078-0432.CCR-12-0552
27. Rosato RR, Almenara JA, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 2007; 67:9490-500; PMID:17909059; http://dx.doi.org/10.1158/0008-5472.CAN-07-0598
28. Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, Grant S. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 2007; 27:5499-513; PMID:17548474; http://dx.doi.org/10.1128/MCB.01080-06
29. Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol 2007; 72:788-95; PMID:17595328; http://dx.doi.org/10.1124/mol.106.033308
30. Llobet D, Eritja N, Yeramian A, Pallares J, Sorolla A, Domingo M, Santacana M, Gonzalez-Tallada FJ, Matias-Guiu X, Dolcet X. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer 2010; 46:836-50; PMID:20071162; http://dx.doi.org/10.1016/j.ejca.2009.12.025
31. Sun NK, Huang SL, Chang TC, Chao CC. Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3beta-dependent protein degradation. J Cell Biochem 2013; 114:1819-31; PMID:23463670; http://dx.doi.org/10.1002/jcb.24530
32. Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, et al. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 2010; 52:1310-21; PMID:20799354; http://dx.doi.org/10.1002/hep.23836
33. Rahmani M, Aust MM, Attkisson E, Williams DC, Jr., Ferreira-Gonzalez A, Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 2012; 119:6089-98; PMID:22446485; http://dx.doi.org/10.1182/blood-2011-09-378141
34. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483:603-7; PMID:22460905; http://dx.doi.org/10.1038/nature11003
35. Settembre C, Fraldi A, Medina DL, Ballabio A. Signals from the lysosome:a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol 2013; 14:283-96; PMID:23609508; http://dx.doi.org/10.1038/nrm3565
36. Parks SK, Chiche J, Pouyssegur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer 2013; 13:611-23; PMID:23969692; http://dx.doi.org/10.1038/nrc3579
37. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005; 5:726-34; PMID:16148885; http://dx.doi.org/10.1038/nrc1692
38. Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke AW, Wang XY, Dai Z, Peng YF, Gu CY, et al. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy 2011; 7:1159-72; PMID:21691147; http://dx.doi.org/10.4161/auto.7.10.16818
39. Luo T, Fu J, Xu A, Su B, Ren Y, Li N, et al. PSMD10/Gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression. Autophagy 2016; 12:1355-71; PMID:25905985; http://dx.doi.org/10.1080/15548627.2015.1034405
40. Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, Burow ME, et al. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res 2011; 71:4955-67; PMID:21622715; http://dx.doi.org/10.1158/0008-5472.CAN-11-0898
41. Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death Dis 2013; 4:e485; PMID:23392173; http://dx.doi.org/10.1038/cddis.2013.18
42. Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu B, Pan S, Dong X, Tan G, Wei Z, et al. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther 2014; 13:1589-98; PMID:24705351; http://dx.doi.org/10.1158/1535-7163.MCT-13-1043
43. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8:445-544; PMID:22966490; http://dx.doi.org/10.4161/auto.19496
44. Gonzalez-Polo RA, Boya P, Pauleau AL, Jalil A, Larochette N, Souquere S, Eskelinen EL, Pierron G, Saftig P, Kroemer G. The apoptosis/autophagy paradox:autophagic vacuolization before apoptotic death. J Cell Sci 2005; 118:3091-102; PMID:15985464; http://dx.doi.org/10.1242/jcs.02447
45. Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 2007; 3:452-60; PMID:17534139; http://dx.doi.org/10.4161/auto.4451
46. Baker BM, Chen CS. Deconstructing the third dimension:how 3D culture microenvironments alter cellular cues. J Cell Sci 2012; 125:3015-24; PMID:22797912; http://dx.doi.org/10.1242/jcs.079509
47. Wiersma VR, de Bruyn M, Wei Y, van Ginkel RJ, Hirashima M, Niki T, Nishi N, Zhou J, Pouwels SD, Samplonius DF, et al. The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. Autophagy 2015; 11:1373-88; PMID:26086204; http://dx.doi.org/10.1080/15548627.2015.1063767
48. Inamoto T, Azuma H. Sorafenib increases endoplasmic reticulum (ER) stress in concert with vorinostat. Cancer Biol Ther 2011; 12:1018; PMID:22095133; http://dx.doi.org/10.4161/cbt.12.12.18135
49. Senft D, Ronai ZA. UPR, autophagy, and mitochondria crosstalk underlies the ER stress response. Trends Biochem Sci 2015; 40:141-8; PMID:25656104; http://dx.doi.org/10.1016/j.tibs.2015.01.002
50. Kang KA, Kim JK, Jeong YJ, Na SY, Hyun JW. Dictyopteris undulata extract induces apoptosis via induction of endoplasmic reticulum stress in human colon cancer cells. J Cancer Prev 2014; 19:118-24; PMID:25337580; http://dx.doi.org/10.15430/JCP.2014.19.2.118
51. Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S. 3,3′-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 2006; 27:717-28; PMID:16332727; http://dx.doi.org/10.1093/carcin/bgi270
52. Zhang R, Kim JS, Kang KA, Piao MJ, Kim KC, Hyun JW. Protective mechanism of KIOM-4 in streptozotocin-induced pancreatic beta-cells damage is involved in the inhibition of endoplasmic reticulum stress. Evid Based Complement Alternat Med 2011; 2011.
53. B'Chir W, Maurin AC, Carraro V, Averous J, Jousse C, Muranishi Y, Parry L, Stepien G, Fafournoux P, Bruhat A. The eIF2alpha/ATF4 pathway is essential for stress-induced autophagy gene expression. Nucleic Acids Res 2013; 41:7683-99; PMID:23804767; http://dx.doi.org/10.1093/nar/gkt563
54. Deegan S, Saveljeva S, Gorman AM, Samali A. Stress-induced self-cannibalism:on the regulation of autophagy by endoplasmic reticulum stress. Cell Mol Life Sci 2013; 70:2425-41; PMID:23052213; http://dx.doi.org/10.1007/s00018-012-1173-4
55. Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP, Ron D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 2000; 287:664-6; PMID:10650002; http://dx.doi.org/10.1126/science.287.5453.664
56. Hagiwara S, Kudo M, Nagai T, Inoue T, Ueshima K, Nishida N, Watanabe T, Sakurai T. Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br J Cancer 2012; 106:1997-2003; PMID:22596232; http://dx.doi.org/10.1038/bjc.2012.145
57. Wang L, Gallo KA, Conrad SE. Targeting mixed lineage kinases in ER-positive breast cancer cells leads to G2/M cell cycle arrest and apoptosis. Oncotarget 2013; 4:1158-71; PMID:23902710; http://dx.doi.org/10.18632/oncotarget.1093
58. Sweeney ZK, Lewcock JW. ACS chemical neuroscience spotlight on CEP-1347. ACS Chem Neurosci 2011; 2:3-4; PMID:22778853; http://dx.doi.org/10.1021/cn1000793
59. Sinha S, Levine B. The autophagy effector Beclin 1:a novel BH3-only protein. Oncogene 2008; 27 Suppl 1:S137-48; PMID:19641499; http://dx.doi.org/10.1038/onc.2009.51
60. Giatromanolaki A, Koukourakis MI, Koutsopoulos A, Chloropoulou P, Liberis V, Sivridis E. High Beclin 1 expression defines a poor prognosis in endometrial adenocarcinomas. Gynecol Oncol 2011; 123:147-51; PMID:21741077; http://dx.doi.org/10.1016/j.ygyno.2011.06.023
61. Peng YF, Shi YH, Ding ZB, Ke AW, Gu CY, Hui B, Zhou J, Qiu SJ, Dai Z, Fan J. Autophagy inhibition suppresses pulmonary metastasis of HCC in mice via impairing anoikis resistance and colonization of HCC cells. Autophagy 2013; 9:2056-68; PMID:24157892; http://dx.doi.org/10.4161/auto.26398
62. Deng L, Feng J, Broaddus RR. The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress. Cell Death Dis 2010; 1:e32; PMID:21072319; http://dx.doi.org/10.1038/cddis.2010.9
63. Orfanelli T, Jeong JM, Doulaveris G, Holcomb K, Witkin SS. Involvement of autophagy in cervical, endometrial and ovarian cancer. Int J Cancer 2014; 135:519-28; PMID:24122662; http://dx.doi.org/10.1002/ijc.28524
64. Lebovitz CB, Robertson AG, Goya R, Jones SJ, Morin RD, Marra MA, et al. Cross-cancer profiling of molecular alterations within the human autophagy interaction network. Autophagy 2015; 11:1668-87; PMID:26208877; http://dx.doi.org/10.1080/15548627.2015.1067362
65. Sivridis E, Giatromanolaki A, Liberis V, Koukourakis MI. Autophagy in endometrial carcinomas and prognostic relevance of ‘stone-like’ structures (SLS):what is destined for the atypical endometrial hyperplasia? Autophagy 2011; 7:74-82; PMID:21099253; http://dx.doi.org/10.4161/auto.7.1.13947
66. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84:1424-31; PMID:11355958; http://dx.doi.org/10.1054/bjoc.2001.1796
67. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, et al. Patient-derived xenograft models:an emerging platform for translational cancer research. Cancer Discov 2014; 4:998-1013; PMID:25185190; http://dx.doi.org/10.1158/2159-8290.CD-14-0001
68. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 3 trial. Lancet 2014; 384:319-28; PMID:24768112; http://dx.doi.org/10.1016/S0140-6736(14)60421-9
69. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90; PMID:18650514; http://dx.doi.org/10.1056/NEJMoa0708857
70. Procopio G, Verzoni E, Testa I, Nicolai N, Salvioni R, Debraud F. Experience with sorafenib in the treatment of advanced renal cell carcinoma. Ther Adv Urol 2012; 4:303-13; PMID:23205057; http://dx.doi.org/10.1177/1756287212457216
71. Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013; 5:345-52; PMID:23898367; http://dx.doi.org/10.4254/wjh.v5.i7.345
72. Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, et al. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer 2012; 131:548-57; PMID:21858812; http://dx.doi.org/10.1002/ijc.26374
73. Honma Y, Harada M. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation. Exp Cell Res 2013; 319:2166-78; PMID:23727131; http://dx.doi.org/10.1016/j.yexcr.2013.05.023
74. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132:27-42; PMID:18191218; http://dx.doi.org/10.1016/j.cell.2007.12.018
75. Allavena G, Carrarelli P, Del Bello B, Luisi S, Petraglia F, Maellaro E. Autophagy is upregulated in ovarian endometriosis:a possible interplay with p53 and heme oxygenase-1. Fertil Steril 2015; 103:1244-51e1; http://dx.doi.org/10.1016/j.fertnstert.2015.02.007
76. Choi J, Jo M, Lee E, Oh YK, Choi D. The role of autophagy in human endometrium. Biol Reprod 2012; 86:70; PMID:22088918; http://dx.doi.org/10.1095/biolreprod.111.096206
77. Zhang L, Liu Y, Xu Y, Wu H, Wei Z, Cao Y. The expression of the autophagy gene beclin-1 mRNA and protein in ectopic and eutopic endometrium of patients with endometriosis. Int J Fertil Steril 2015; 8:429-36; PMID:25780525
78. Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell 2008; 30:678-88; PMID:18570871; http://dx.doi.org/10.1016/j.molcel.2008.06.001
79. Luo S, Garcia-Arencibia M, Zhao R, Puri C, Toh PP, Sadiq O, Rubinsztein DC. Bim inhibits autophagy by recruiting Beclin 1 to microtubules. Mol Cell 2012; 47:359-70; PMID:22742832; http://dx.doi.org/10.1016/j.molcel.2012.05.040
80. Kenific CM, Thorburn A, Debnath J. Autophagy and metastasis:another double-edged sword. Curr Opin Cell Biol 2010; 22:241-5; PMID:19945838; http://dx.doi.org/10.1016/j.ceb.2009.10.008
81. Herranz D, Ambesi-Impiombato A, Sudderth J, Sanchez-Martin M, Belver L, Tosello V, Xu L, Wendorff AA, Castillo M, Haydu JE, et al. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nat Med 2015; 21:1182-9; PMID:26390244; http://dx.doi.org/10.1038/nm.3955
82. Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res 2008; 68:1485-94; PMID:18316613; http://dx.doi.org/10.1158/0008-5472.CAN-07-0562
83. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119:1109-23; PMID:19363292; http://dx.doi.org/10.1172/JCI35660
84. Shingu T, Fujiwara K, Bogler O, Akiyama Y, Moritake K, Shinojima N, Tamada Y, Yokoyama T, Kondo S. Stage-specific effect of inhibition of autophagy on chemotherapy-induced cytotoxicity. Autophagy 2009; 5:537-9; PMID:19270491; http://dx.doi.org/10.4161/auto.5.4.8164
85. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One 2009; 4:e6251; PMID:19606230; http://dx.doi.org/10.1371/journal.pone.0006251
86. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, et al. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 2011; 17:5793-800; PMID:21742805; http://dx.doi.org/10.1158/1078-0432.CCR-11-0341
87. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007; 13:3989-98; PMID:17606733; http://dx.doi.org/10.1158/1078-0432.CCR-07-0078
88. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011; 10:1311-6; PMID:21673092; http://dx.doi.org/10.1158/1535-7163.MCT-11-0233
89. Eritja N, Llobet D, Domingo M, Santacana M, Yeramian A, Matias-Guiu X, Dolcet X. A novel three-dimensional culture system of polarized epithelial cells to study endometrial carcinogenesis. Am J Pathol 2010; 176:2722-31; PMID:20395448; http://dx.doi.org/10.2353/ajpath.2010.090974
90. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal:an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2:401-4; PMID:22588877; http://dx.doi.org/10.1158/2159-8290.CD-12-0095
91. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6:pl1; PMID:23550210; http://dx.doi.org/10.1126/scisignal.2004088
92. Hubbell E, Liu WM, Mei R. Robust estimators for expression analysis. Bioinformatics 2002; 18:1585-92; PMID:12490442; http://dx.doi.org/10.1093/bioinformatics/18.12.1585
93. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene ontology:tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25:25-9; PMID:10802651; http://dx.doi.org/10.1038/75556
94. Burgess A, Vigneron S, Brioudes E, Labbe JC, Lorca T, Castro A. Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. Proc Natl Acad Sci U S A 2010; 107:12564-9; PMID:20538976; http://dx.doi.org/10.1073/pnas.0914191107
95. McCloy RA, Rogers S, Caldon CE, Lorca T, Castro A, Burgess A. Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. Cell Cycle 2014; 13:1400-12; PMID:24626186; http://dx.doi.org/10.4161/cc.28401